热线电话: 021-34661275
产品分类/PRODUCT CLASSIFICATION

上海细胞库

人源细胞系| 稳转细胞系| 基因敲除株| 基因点突变细胞株| 基因过表达细胞株| 重组细胞系| 猪的细胞系| 马细胞系| 兔的细胞系| 犬的细胞系| 山羊的细胞系| 鱼的细胞系| 猴的细胞系| 仓鼠的细胞系| 狗的细胞系| 牛的细胞| 大鼠细胞系| 小鼠细胞系| 其他细胞系|

原代细胞

原代细胞| 永生化细胞|

细胞培养

血清| 无血清冻存| 细胞培养试剂盒| 普通培养基| 完全培养基| 细胞污染预防| 细胞污染清除| 细胞培养辅助试剂|

细胞服务

STR鉴定服务| ATCC代购服务|

酶联试剂盒

人ELISA试剂盒| 大鼠ELISA试剂盒| 小鼠ELISA试剂盒| 兔ELISA试剂盒| 猪ELISA试剂盒| 鱼ELISA试剂盒| 牛ELISA试剂盒| 犬ELISA试剂盒| 鸭ELISA试剂盒| 豚鼠ELISA试剂盒| 鸡ELISA试剂盒| 绵羊ELISA试剂盒| 山羊ELISA试剂盒| 仓鼠ELISA试剂盒| 植物ELISA试剂盒| 药残留类试剂盒| 其他ELISA试剂盒|

生化试剂盒

生化试剂盒| 微量法检测盒| 分光法检测盒| 胶体金检测盒|

PCR试剂盒

荧光探针PCR试剂盒| 染料荧光PCR试剂盒| 核酸扩增/纯化| 普通PCR检测试剂盒| 质粒菌种感受态|

抗体蛋白

蛋白多肽| 抗体| 免疫组化| 免疫球蛋白|

试剂耗材

标准试液| 科研试剂| 缓 冲 液| 实验耗材| 高效液相色谱对照品|

首页 > 抗体蛋白 > 抗体
Brilliant Violet 421™ anti-mouse IFN-γ
产品名称：
Brilliant Violet 421™ anti-mouse IFN-γ
产品类别：
抗体
产品编号：
505829
产品应用：
505829
[价格]
规格 价格 库存
125µL ￥ 2772 1

产品详情

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
E. coli-expressed, recombinant mouse IFN-γ
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421? under optimal conditions.
Concentration
?g sizes: 0.2 mg/mL
?L sizes: lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

ICFC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the ?g size, the suggested use of this reagent is ≤0.1 ?g per million cells in 100 ?l volume. For immunofluorescent staining using the ?l size, the suggested use of this reagent is 5 ?l per million cells in 100 ?l staining volume or 5 ?l per 100 ?l of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 421? excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421? is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet?.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

ELISA1-4,11,14 or ELISPOT5 Detection: The biotinylated XMG1.2 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with purified R4-6A2 antibody (Cat. No. 505702/505706) as the capture antibody and recombinant mouse IFN-? (Cat. No. 575309) as the standard.
ELISA or ELISPOT Capture: The purified XMG1.2 antibody is useful as a capture antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with biotinylated R4-6A2 antibody (Cat. No. 505704) as the detection antibody and recombinant mouse IFN-? (Cat. No. 575309) as the standard. The LEAF? purified antibody is suggested for ELISPOT capture (Cat. No. 505812).
Flow Cytometry7,8,12,13,16: The fluorochrome-labeled XMG1.2 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IFN-?-producing cells within mixed cell populations.
Neutralization1-3,9,10: The XMG1.2 antibody can neutralize the bioactivity of natural or recombinant IFN-?. The LEAF? purified antibody (Endotoxin <0.1 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for neutralization of mouse IFN-? bioactivity in vivo and in vitro (Cat. No. 505812). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF? purified antibody (Cat. No. 505834) with a lower endotoxin limit than standard LEAF? purified antibodies (Endotoxin <0.01 EU/?g).
Additional reported applications (for the relevant formats) include: Western blotting, immunohistochemical staining of frozen tissue sections6,22,23, and immunocytochemistry.
Note: For testing mouse IFN-? in serum, plasma or supernatant, BioLegend's ELISA Max? Sets (Cat. No. 430801 to 430806) are specially developed and recommended.

Application References

(PubMed link indicates BioLegend citation)
  1. Abrams J, et al. 1992. Immunol. Rev. 127:5. (ELISA, Neut)
  2. Sander B, et al. 1993. J. Immunol. Meth. 166:201. (ELISA, Neut)
  3. Abrams J, et al. 1995. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.20. (ELISA, Neut)
  4. Yang X, et al. 1993. J. Immunoassay 14:129. (ELISA)
  5. Klinman D, et al. 1994. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.19. (ELISPOT)
  6. Sander B, et al. 1991. Immunol. Rev. 119:65. (IHC)
  7. Ferrick D, et al. 1995. Nature 373:255. (FC)
  8. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  9. Peterson KE, et al. 2000. J. Virol. 74:5363. (Neut)
  10. DeKrey GK, et al. 1998. Infect. Immun. 66:827. (Neut)
  11. Dzhagalov I, et al. 2007. J. Immunol. 178:2113. (ELISA)
  12. Lawson BR, et al. 2007. J. Immunol. 178:5366. (FC)
  13. Lee JW, et al. 2006. Nature Immunol. 8:181. (FC) PubMed
  14. Xu G, et al. 2007. J. Immunol. 179:5358. (ELISA) PubMed
  15. Montfort M, et al.2004. J. Immunol. 173:4084. PubMed
  16. Haring JS, et al. 2008. J. Immunol. 180:2855. (FC) PubMed
  17. Jordan JM, et al. 2008. Infect Immun. 76:3717. PubMed
  18. Tonkin DR, et al. 2008. J. Immunol. 181:4516. PubMed
  19. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
  20. Cui Y, et al. 2009. Invest. Ophth. Vis. Sci. 50:5811. (FC) PubMed
  21. Mykkanen OT, et al. 2014. PLoS One. 9:114790. PubMed
  22. Yokogawa M, et al. 2013. Mol. Carcinog. 52:760. (IHC)
  23. Mottram PL, et al. 1998. J Immunol. 161:602. (IHC)
Product Citations
  1. Harsha Krovi S, et al. 2020. Nat Commun. 4.790277778. PubMed
  2. Soon MSF, et al. 2020. Nat Immunol. 1.984027778. PubMed
  3. Wang X, et al. 2019. Cell Res. 29:787. PubMed
  4. Weulersse M, et al. 2020. Immunity. 53(4):824-839.e10. PubMed
  5. Singer M et al. 2016. Cell. 166(6):1500-1511 . PubMed
  6. Page N, et al. 2018. Immunity. 48:937. PubMed
  7. Quatrini L, et al. 2018. Nat Immunol. 19:954. PubMed
  8. Manivasagam S, et al. 2022. J Immunol. 208:1341. PubMed
  9. Gruber T, et al. 2020. JCI Insight. 5:00. PubMed
  10. Kremenovic M, et al. 2022. J Immunother Cancer. 10:. PubMed
  11. Feizi N, et al. 2021. Cell Death Dis. 12:1026. PubMed
  12. Peng Z, et al. 2021. STAR Protocols. 2(2):100595. PubMed
  13. Jtte BB, et al. 2021. iScience. 24(8):102833. PubMed
  14. Wang W, et al. 2020. Br J Pharmacol. 177:5569. PubMed
  15. Gajdasik DW, et al. 2020. Nat Commun. 2.834027778. PubMed
  16. Runge EM, et al. 2020. J Neuroinflammation. 17:121. PubMed
  17. Perrot I et al. 2019. Cell Rep. 27(8):2411-2425 . PubMed
  18. Jia L, et al. 2022. Front Immunol. 13:897879. PubMed
  19. Rao TN, et al. 2020. J Immunol. 204:2600. PubMed
  20. van der Lelie D, et al. 2021. Nat Commun. 12:3105. PubMed
  21. Snyder LM, et al. 2022. Immunohorizons. 6:660. PubMed
  22. Bunn P, et al. 2014. J Immunol. 192:3709. PubMed
  23. Lian J, et al. 2020. Cell Reports. 31(8):107679. PubMed
  24. Imani J, et al. 2021. JCI Insight. 6:. PubMed
  25. Du Y, et al. 2022. Nat Commun. 13:231. PubMed
  26. Kim E, et al. 2022. STAR Protoc. 3:101366. PubMed
  27. Novince CM, et al. 2017. Sci Rep. 7:5747. PubMed
  28. Bankoti R, et al. 2017. Sci Rep. 10.1038/s41598-017-12171-3. PubMed
  29. Luck H, et al. 2015. Cell Metab. 21 527 . PubMed
  30. Liu S, et al. 2020. Cell Host & Microbe. 26(6):779-794.e8.. PubMed
  31. Gebre MS, et al. 2022. NPJ Vaccines. 7:88. PubMed
  32. Ying Zhang et al. 2017. Cancer cell. 32(3):377-391 . PubMed
  33. Pathania AS, et al. 2022. Mol Ther Oncolytics. 25:308. PubMed
  34. Montfort M, et al. 2004. J Immunol. 173:4084. PubMed
  35. Yang E, et al. 2016. J Immunol. 197: 934 - 941. PubMed
  36. Luck H, et al. 2019. Nat Commun. 10:3650. PubMed
  37. Yu M, et al. 2021. Molecular Cell. 81(6):1216-1230.e9. PubMed
  38. Clancy–Thompson E, et al. 2019. EMBO J. 38:e101260. PubMed
  39. Kiuchi M, et al. 2021. J Exp Med. 218:. PubMed
  40. Wang J, et al. 2022. Clin Transl Med. 12:e718. PubMed
  41. Sebina I, et al. 2016. PLoS Pathog. 12:e1005999. PubMed
  42. Lee J, et al. 2007. Nat Immunol. 8:181. PubMed
  43. Montes de Oca M, et al. 2016. PLoS Pathog. 12: 1005398. PubMed
  44. Webb LM, et al. 2020. J Clin Invest. 130:1683. PubMed
  45. Ren S, et al. 2022. Int J Biol Sci. 18:166. PubMed
  46. Tzeng TT, et al. 2022. NPJ Vaccines. 7:60. PubMed
  47. Xiao Z, et al. 2022. Mater Today Bio. 15:100297. PubMed
  48. Deng J, et al. 2021. EBioMedicine. 70:103505. PubMed
  49. Heckler M, et al. 2021. Cancer Discov. Online ahead of prin. PubMed
  50. Wang J, et al. 2020. J Hematol Oncol. 0.610416667. PubMed
  51. Spiljar M, et al. 2021. Cell Metab. 33:2231. PubMed
  52. Luo Z, et al. 2021. Int J Mol Sci. 22:. PubMed
  53. Tsai S, et al. 2018. Cell Metab. 28:922. PubMed
  54. Song X, et al. 2022. Transl Oncol. 15:101306. PubMed
  55. Li H, et al. 2021. Signal Transduct Target Ther. 6:389. PubMed
  56. Conforti A, et al. 2021. Mol Ther. S1525-0016:00466. PubMed
  57. Li X, et al. 2021. Front Cell Dev Biol. 9:647713. PubMed
RRID
AB_10897937 (BioLegend Cat. No. 505829) AB_2563105 (BioLegend Cat. No. 505830)

Antigen Details

Structure
Cytokine; dimer; 40-80 kD (Mammalian)
Bioactivity
Antiviral/antiparasitic activities; inhibits proliferation; enhances MHC class I and II expression on APCs
Cell Sources
CD8+ and CD4+ T cells, NK cells
Cell Targets
T cells, B cells, macrophages, NK cells, endothelial cells, fibroblasts
Receptors
IFN-γRα (CDw119) dimerized with IFN-γRβ (AF-1)
Cell Type
Tregs
Biology Area
Cell Biology, Immunology, Neuroinflammation, Neuroscience
Molecular Family
Cytokines/Chemokines
Antigen References

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego.
2. De Maeyer E, et al. 1992. Curr. Opin. Immunol. 4:321.
3. Farrar M, et al. 1993. Annu. Rev. Immunol. 11:571.
4. Gray P, et al. 1987. Lymphokines 13:151.

Regulation
Upregulated by IL-2, FGF-basic, EGF; downregulated by 1-α-25-Dihydroxy vitamin D3, dexamethasone
Gene ID
15978 View all products for this Gene ID
UniProt
View information about IFN-gamma on UniProt.org

联系我们

TEL：021-34661275 　点击拨打热线